{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:02:20Z","timestamp":1772967740127,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T00:00:00Z","timestamp":1239840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s10067-009-1179-y","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T03:39:38Z","timestamp":1239766778000},"page":"1001-1003","source":"Crossref","is-referenced-by-count":45,"title":["Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept"],"prefix":"10.1007","volume":"28","author":[{"given":"K. M.","family":"Carlsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Riis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. R.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,16]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K et al (2008) The comparative performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthrtis Rheum 59:234\u2013240","journal-title":"Arthrtis Rheum"},{"key":"1179_CR2","first-page":"CD006893","volume":"23","author":"BW Behm","year":"2008","unstructured":"Behm BW, Bickston SJ (2008) Tumor necrosis factor-alfa antibody for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 23:CD006893","journal-title":"Cochrane Database Syst Rev"},{"key":"1179_CR3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2474-9-52","volume":"9","author":"A Alonso-Ruiz","year":"2008","unstructured":"Alonso-Ruiz A, Pijoan JI, Ansuategui E et al (2008) Tumor necrosis factor alpha drugs in rheumatois arthritis: systematic review and metaanalysis of efficacy and safety. BMC Muskuloskelet Disord 9:52","journal-title":"BMC Muskuloskelet Disord"},{"key":"1179_CR4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","volume":"62","author":"P Ostuni","year":"2003","unstructured":"Ostuni P, Botsios C, Punzi L et al (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686\u2013687","journal-title":"Ann Rheum Dis"},{"key":"1179_CR5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ard.2004.031187","volume":"64","author":"D Wendling","year":"2005","unstructured":"Wendling D, Auge B, Bettinger D et al (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64:788\u2013789","journal-title":"Ann Rheum Dis"},{"key":"1179_CR6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","volume":"64","author":"V Germano","year":"2005","unstructured":"Germano V, Diamanti AP, Baccano G et al (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64:1519\u20131520","journal-title":"Ann Rheum Dis"},{"key":"1179_CR7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1157\/13087475","volume":"29","author":"S Soto-Fernandez","year":"2006","unstructured":"Soto-Fernandez S, Gonzalez-Carro P, De Pedro-Esteban A et al (2006) Infliximab-induced hepatitis in a patient with Crohn's disease. Gastroenterol Hepatol 29:321\u2013322","journal-title":"Gastroenterol Hepatol"},{"key":"1179_CR8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2230.2006.02086.x","volume":"31","author":"S Wahie","year":"2006","unstructured":"Wahie S, Alexandroff A, Reynolds NJ (2006) Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 31:460\u2013461","journal-title":"Clin Exp Dermatol"},{"key":"1179_CR9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ibd.20293","volume":"14","author":"M Marques","year":"2007","unstructured":"Marques M, Magro F, Cardoso H et al (2007) Infliximab-induced lupus like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 14:723\u2013725","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1179_CR10","first-page":"1098","volume":"31","author":"KE Hansen","year":"2004","unstructured":"Hansen KE, Hildebrand JP, Genovese MC et al (2004) The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31(6):1098\u20131102","journal-title":"J Rheumatol"},{"key":"1179_CR11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","volume":"75","author":"G Thi\u00e9fin","year":"2008","unstructured":"Thi\u00e9fin G, Morelet A, Heurgu\u00e9 A et al (2008) Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75:737\u2013739","journal-title":"Joint Bone Spine"},{"key":"1179_CR12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-006-0253-y","volume":"26","author":"AM Garc\u00eda Aparicio","year":"2007","unstructured":"Garc\u00eda Aparicio AM, Rey JR, Sanz AH et al (2007) Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26:811\u2013813","journal-title":"Clin Rheumatol"},{"key":"1179_CR13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/ard.2003.006775","volume":"63","author":"M Feletar","year":"2004","unstructured":"Feletar M, Brockbank JE, Schentag CT et al (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12\u00a0month observational study of 16 patients. Ann Rheum Dis 63:156\u2013161","journal-title":"Ann Rheum Dis"},{"key":"1179_CR14","unstructured":"Provenzano G (2004) Liver toxicity of infliximab in psoriatic arthritis. Ann Rheum Dis June 24: e-letter"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1179-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-009-1179-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1179-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:51:35Z","timestamp":1559105495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-009-1179-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,16]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s10067-009-1179-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,16]]}}}